Sanela Bilic

Bioanalysis of Antibody–Drug Conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group Position Paper

Boris Gorovits, Stephen C. Alley, Sanela Bilic et al. · Bioanalysis · 2013 · 164 citations

American Association, Immunology, Medicinal Chemistry +17

A Phase <scp>IB</scp> multicentre dose‐determination study of <scp>BHQ</scp>880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events

Swaminathan P. Iyer, Joseph Taddeus Beck, A. Keith Stewart et al. · British Journal of Haematology · 2014 · 153 citations · Full text

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

Seth A. Ettenberg, Olga Charlat, Shanming Liu et al. · Proceedings of the National Academy of Sciences · 2010 · 153 citations · Full text

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor

Kyriakos P. Papadopoulos, Randi Isaacs, Sanela Bilic et al. · Cancer Chemotherapy and Pharmacology · 2015 · 149 citations

Nanomedicine, Drug Target, Drug Targeting +9

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

John C. Byrd, Thomas J. Kipps, Ian W. Flinn et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2012 · 111 citations · Full text

Chronic Lymphocytic Leukemia, Immunology, Anti-cd40 Antibody +18